228 related articles for article (PubMed ID: 18975354)
81. Plasma adiponectin in patients with active, early, and chronic rheumatoid arthritis who are steroid- and disease-modifying antirheumatic drug-naive compared with patients with osteoarthritis and controls.
Laurberg TB; Frystyk J; Ellingsen T; Hansen IT; Jørgensen A; Tarp U; Hetland ML; Hørslev-Petersen K; Hornung N; Poulsen JH; Flyvbjerg A; Stengaard-Pedersen K
J Rheumatol; 2009 Sep; 36(9):1885-91. PubMed ID: 19684150
[TBL] [Abstract][Full Text] [Related]
82. Reply: To PMID 25371395.
Gregersen PK; Oswald M; Curran M; Carulli J;
Arthritis Rheumatol; 2015 May; 67(8):2277. PubMed ID: 25989099
[No Abstract] [Full Text] [Related]
83. Association of methotrexate effects and single-nucleotide polymorphisms in the folate pathway in rheumatoid arthritis: comment on the article by Wessels et al.
Ranganathan P
Arthritis Rheum; 2006 Oct; 54(10):3372; author reply 3372-3. PubMed ID: 17009311
[No Abstract] [Full Text] [Related]
84. Comment on: Modelling the cost effectiveness of TNF antagonists in the management of rheumatoid arthritis: results from the British Society for Rheumatology Biologics Registry.
van Vollenhoven RF;
Rheumatology (Oxford); 2008 Jul; 47(7):1106-7; author reply 1107. PubMed ID: 18326533
[No Abstract] [Full Text] [Related]
85. What is meant by active disease in the NICE recommendation on use of combination therapy in early RA?
Ezard C; Kumari R; Willott R; Butt S; Gadsby K; Deighton C
Rheumatology (Oxford); 2012 May; 51(5):947-8. PubMed ID: 22298791
[No Abstract] [Full Text] [Related]
86. RANK/RANKL: regulators of immune responses and bone physiology.
Leibbrandt A; Penninger JM
Ann N Y Acad Sci; 2008 Nov; 1143():123-50. PubMed ID: 19076348
[TBL] [Abstract][Full Text] [Related]
87. Early and aggressive treatment affects the association of HLA-DRB1 genes with progression of joint damage: comment on the article by Lard et al.
Rau R; Herborn G; Fenner H
Arthritis Rheum; 2003 Feb; 48(2):579. PubMed ID: 12571873
[No Abstract] [Full Text] [Related]
88. The effect of smoking on response and drug survival in rheumatoid arthritis patients treated with their first anti-TNF drug: comments on the article by Söderlin et al.
Park SJ; Shin JI
Scand J Rheumatol; 2012 Oct; 41(5):411-2. PubMed ID: 23043533
[No Abstract] [Full Text] [Related]
89. Inhibiting citrullination in rheumatoid arthritis: taking fuel from the fire.
Fisher BA; Venables PJ
Arthritis Res Ther; 2012 Feb; 14(1):108. PubMed ID: 22380578
[TBL] [Abstract][Full Text] [Related]
90. Glycosaminoglycans as potential regulators of osteoprotegerin therapeutic activity in osteosarcoma.
Lamoureux F; Picarda G; Garrigue-Antar L; Baud'huin M; Trichet V; Vidal A; Miot-Noirault E; Pitard B; Heymann D; Rédini F
Cancer Res; 2009 Jan; 69(2):526-36. PubMed ID: 19147566
[TBL] [Abstract][Full Text] [Related]
91. Therapeutic implications for interferon-alpha in arthritis.
Kötter I; Stübiger N
J Rheumatol; 2004 Mar; 31(3):624-5; author reply 625. PubMed ID: 14994421
[No Abstract] [Full Text] [Related]
92. RANKL increases vascular smooth muscle cell calcification through a RANK-BMP4-dependent pathway.
Panizo S; Cardus A; Encinas M; Parisi E; Valcheva P; López-Ongil S; Coll B; Fernandez E; Valdivielso JM
Circ Res; 2009 May; 104(9):1041-8. PubMed ID: 19325147
[TBL] [Abstract][Full Text] [Related]
93. The HLA-B27 transgenic rat, a model of spondyloarthritis, has decreased bone mineral density and increased RANKL to osteoprotegerin mRNA ratio.
Rauner M; Stupphann D; Haas M; Fert I; Glatigny S; Sipos W; Breban M; Pietschmann P
J Rheumatol; 2009 Jan; 36(1):120-6. PubMed ID: 19040304
[TBL] [Abstract][Full Text] [Related]
94. The case against haste in the treatment of rheumatoid arthritis: comment on the editorial by Pincus et al.
Epstein WV
Arthritis Rheum; 2003 Feb; 48(2):573-5; author reply 576-9. PubMed ID: 12571870
[No Abstract] [Full Text] [Related]
95. Thromboxane synthase mutations in an increased bone density disorder (Ghosal syndrome).
Geneviève D; Proulle V; Isidor B; Bellais S; Serre V; Djouadi F; Picard C; Vignon-Savoye C; Bader-Meunier B; Blanche S; de Vernejoul MC; Legeai-Mallet L; Fischer AM; Le Merrer M; Dreyfus M; Gaussem P; Munnich A; Cormier-Daire V
Nat Genet; 2008 Mar; 40(3):284-6. PubMed ID: 18264100
[TBL] [Abstract][Full Text] [Related]
96. CD22 is not expressed merely on B cells: comment on the article by Vos et al.
Teng YK; Engels MC; van Laar JM
Arthritis Rheum; 2008 Mar; 58(3):911-2; author reply 912-3. PubMed ID: 18311823
[No Abstract] [Full Text] [Related]
97. Matrix catabolism in arthritis: priming the guns with oncostatin M.
Richards CD
J Rheumatol; 2004 Dec; 31(12):2326-8. PubMed ID: 15570629
[No Abstract] [Full Text] [Related]
98. An angiotensin receptor blocker suppresses monocyte chemoattractant protein 1 production from rheumatoid synovial fibroblasts: comment on the article by Sagawa et al.
Iikuni N; Okamoto H; Kasahara M; Kamatani N
Arthritis Rheum; 2005 Dec; 52(12):4047-8. PubMed ID: 16320355
[No Abstract] [Full Text] [Related]
99. Folic acid and folinic acid supplements and methotrexate therapy: comment on the article by Morgan et al.
Cronstein BN
Arthritis Rheum; 2005 Apr; 52(4):1338-9; author reply 1339-40. PubMed ID: 15818677
[No Abstract] [Full Text] [Related]
100. Inflamed joints and stiff arteries: is rheumatoid arthritis a cardiovascular risk factor?
Quyyumi AA
Circulation; 2006 Sep; 114(11):1137-9. PubMed ID: 16966595
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
